Pharmaceutical Development & Medical Cannabis Expand at an Aggressive Rate - Company Attracts Major Attention at WebCongress Conference in San Francisco

May 16, 2014, 09:20 ET from FN Media Group, LLC

CORAL SPRINGS, Florida, May 16, 2014 /PRNewswire/ --

Pharmaceutical Business Development for Pharma and Cannabis oriented operations continues steady growth as companies develop and garner attention: Cannabis Capital Corp. (OTCBB: CBCA), GW Pharmaceuticals plc (NASDAQ: GWPH), Medbox, Inc. (OTC: MDBX), Rexahn Pharmaceuticals, Inc. (NYSE: RNN) and Northwest Biotherapeutics, Inc. (NASDAQ: NWBO)

Cannabis Capital Corp. (OTCQB: CBCA) is an emerging global firm specializing in business development, high tech pharmaceutical development, and medical technology. The Company is proud to announce that WebCongress, Inc., a wholly-owned subsidiary of the Company, held a very successful conference in San Francisco, the first in the 2014 'Americas Tour' series. Together with the evening Networking event organized by StartUpSocials, WebCongress San Francisco gathered 569 attendees on May 8, 2014.

WebCongress San Francisco 2014 

"San Francisco, being a geographic leader in tech, demands more educational content in this space, such as through events, seminars, webinars, and consulting," said Ouali Benmeziane, CEO & Founder of WebCongress. "We are proud to bring the WebCongress experience and exchange knowledge with area businesses, and we look forward to returning to San Francisco soon with additional content and inspiring speakers, building on new and exciting partnerships with leading internet companies."

To read the full CBCA press release, please click here:

"Two weeks prior to the event, the WebCongress team was invited to visit and connect with San Francisco Bay area powerhouses, such as Google, AirBnb, Women 2.0, Rocketspace, and Adobe," noted Chad S. Johnson, CEO of CBCA. "WebCongress is quickly establishing itself as the standard in the industry."

GW Pharmaceuticals plc (NASDAQ: GWPH), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform, recently announced that the Company has received confirmation from the U.S. Food and Drug Administration (FDA) that its Investigational New Drug application (IND) is now open for Epidiolex in the treatment of Dravet Syndrome, a rare and catastrophic treatment-resistant form of childhood epilepsy. GW expects to commence a Phase 2/3 clinical trial in the second half of 2014. Epidiolex has already received orphan drug designation from the FDA for the treatment of Dravet syndrome. "The acceptance of this IND by the FDA is a significant milestone for Epidiolex and for children with Dravet syndrome for whom existing anti-epileptic medicines often do not provide adequate relief," stated Justin Gover, GW's Chief Executive Officer. "This journey began with requests from the U.S. epilepsy physician and patient community to utilize Epidiolex and has now led to GW embarking on its own formal development program with a view to seeking market authorization from the FDA as rapidly as possible. We are committed to providing a prescription cannabidiol (CBD) medicine for children with Dravet syndrome who have exhausted all other therapeutic options."

Medbox, Inc. (OTCQB: MDBX) recently announced that its company information would be made available via S&P Capital IQ Corporation Records Listing Program.  As part of the program, a full description of Medbox, Inc., will be published in the Daily News Section of Standard & Poors's Corporation Records, a recognized securities manual for secondary trading in up to 38 States under the Blue Sky Laws.  S&P Capital IQ Corporation Records is available in print, CD-ROM, and via the web at as well as through numerous electronic vendors. The company information about Medbox, Inc. to be made available through this program includes an in-depth description of the Medbox, Inc's. business operations, share price, dividend history, shares outstanding, company financial position, earnings, and full income statement and balance sheet.

Rexahn Pharmaceuticals, Inc. (NYSE: RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced additional data from preclinical studies on the anti-tumor effects of RX-3117, a next generation cancer cell specific nucleoside analog. In the study, oral administration of RX-3117 inhibited tumor growth in 12 different human cancer xenograft models including colon, non-small cell lung, small cell lung, pancreatic, renal, ovarian, and cervical cancer. In addition, RX-3117 inhibited the growth of human cancer cells lines shown to be resistant to the anti-cancer effects of gemcitabine, including in the primary low-passage human pancreatic tumorgraft model. "Resistance to the anti-cancer effects of gemcitabine represents a major clinical issue in the treatment of cancer patients. Up to 25% of cancer patients receiving one or more cycles of gemcitabine rapidly become resistant to its anti-cancer activity. Based on study results to date, both preclinical and clinical, we believe RX-3117 holds the potential to be used for the treatment of tumors that do not respond to gemcitabine and other chemotherapeutic drugs," commented Rexahn's CEO, Peter D. Suzdak, Ph.D.

Northwest Biotherapeutics, Inc. (NASDAQ: NWBO), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, recently provided an initial patient case study, showing signs of tumor necrosis (tumor death) and initial tumor regression, from the Company's ongoing DCVax-Direct trial for all types of inoperable solid tumors. The Company plans to announce further case study information prior to the annual ASCO conference, while it continues collecting data from the trial. Although the trial is still at an early stage, with many of the patients only part way through the treatment regimen, the Company also plans to provide overall information about the data to date by the time of the ASCO conference. The specific case study announced today involves a sarcoma patient with a large tumor mass and multiple inoperable metastatic tumors in the lung. This patient received the first 3 DCVax-Direct injections through the course of a month, starting in February. He received a fourth injection in early April and then was scanned for results in early May. At that time, this patient's MRI scan showed extensive necrosis and partial collapse of the injected large tumor mass, and a CT scan showed some early indication of shrinkage of one of the non-injected metastasized tumors. These results suggest both local and systemic effects of the DCVax-Direct treatment, as were seen in the pre-clinical studies. is leading provider of third party publishing & news dissemination services. If you would like more information regarding our news coverage solutions, please visit for more details. Get an edge on the market with our Premium News Alerts that are FREE for a limited time at Follow us on Facebook: and Twitter: 

DISCLAIMER:  FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNMG was compensated one thousand seven hundred dollars for Cannabis Capital Corp. news coverage by the company.


This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

Contact Information: Company:  FN Media Group, LLC Contact email: U.S. Phone: +1(954)345-0611 URL:


SOURCE FN Media Group, LLC